Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Surgery ; 164(6): 1191-1197, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30154017

RESUMEN

BACKGROUND: Cold-inducible RNA-binding protein is a novel damage-associated molecular pattern that causes inflammation. C23, a short peptide derived from cold-inducible RNA-binding protein, has been found to have efficacy in blocking cold-inducible RNA-binding protein's activity. We hypothesized that C23 reduces inflammation and tissue injury induced by intestinal ischemia-reperfusion. METHODS: Male C57BL/6 mice were subjected to 60 minutes of intestinal ischemia by clamping the superior mesenteric artery. Immediately after reperfusion, either normal saline (vehicle) or C23 peptide (8 mg/kg body weight) was injected intraperitoneally. Four hours after reperfusion, blood, intestinal, and lung tissues were collected for analysis of inflammatory and tissue injury parameters. RESULTS: Cold-inducible RNA-binding protein levels in the intestinal tissues were significantly increased following intestinal ischemia-reperfusion. Histologic examination of the intestine revealed a significant reduction in injury score in the C23 group by 48% as compared with the vehicles after intestinal ischemia-reperfusion. The serum levels of lactate dehydrogenase and aspartate aminotransferase were increased in animals that underwent vehicle-treated intestinal ischemia-reperfusion, whereas C23-treated animals exhibited significant reductions by 48% and 53%, respectively. The serum and intestinal tissue levels of tumor necrosis factor α were elevated in vehicle-treated intestinal ischemia-reperfusion mice but decreased by 72% and 69%, respectively, in C23-treated mice. Interleukin-6 mRNA levels in the lungs were reduced by 86% in the C23-treated group in comparison to the vehicle-treated group after intestinal ischemia-reperfusion. Expression of macrophage inflammatory protein 2 and level of myeloperoxidase activity in the lungs were dramatically increased after intestinal ischemia-reperfusion and significantly reduced by 91% and 25%, respectively, in the C23-treated group. CONCLUSION: C23 has potential to be developed into a possible therapy for reperfusion injury after mesenteric ischemia and reperfusion.


Asunto(s)
Enfermedades Pulmonares/prevención & control , Glicoproteínas de Membrana/agonistas , Isquemia Mesentérica/prevención & control , Fosfoproteínas/uso terapéutico , Proteínas de Unión al ARN/uso terapéutico , Receptores de Superficie Celular/agonistas , Daño por Reperfusión/prevención & control , Alarminas , Animales , Quimiocina CXCL2/metabolismo , Evaluación Preclínica de Medicamentos , Interleucina-6/metabolismo , Pulmón/metabolismo , Enfermedades Pulmonares/etiología , Enfermedades Pulmonares/metabolismo , Masculino , Isquemia Mesentérica/sangre , Isquemia Mesentérica/inmunología , Ratones Endogámicos C57BL , Peroxidasa/metabolismo , Fosfoproteínas/farmacología , Proteínas de Unión al ARN/sangre , Proteínas de Unión al ARN/farmacología , Daño por Reperfusión/sangre , Daño por Reperfusión/complicaciones , Daño por Reperfusión/inmunología , Factor de Necrosis Tumoral alfa/sangre , Nucleolina
2.
J Drug Target ; 26(3): 222-230, 2018 03.
Artículo en Inglés | MEDLINE | ID: mdl-28701059

RESUMEN

This study was conducted to evaluate the efficacy and possible mechanism of Brucea javanica oil emulsion (BJOE) on cachexia, by observing changes in related indexes in mice with cachexia and identifying the genes responsible based on gene chip analysis. In the BJOE treatment group, body weight loss, tumour growth and metastasis were found obviously inhibited, food and water intake had markedly increased, and survival time was significantly prolonged, as compared to the control group. Moreover, the BJOE witnessed improvement in body weight, prevention of tumour metastasis and overall increase in survival time, as compared to Indometacin (IND, the positive control medicine). It was also found that TNF-α and IL-6 in serum were significantly lower in both groups of BJOE and IND, than in the control group (p < .01). Based on the gene expression data, seven and six hub genes of BJOE and IND groups were found in the potential prognostic impacts networks, and three common genes comprising of Nmd3, Bcl2 and Nhp2l1 were screened. Thus, BJOE could reduce tumour growth and effectively alleviate cancer cachexia, due to inhibition of pro-inflammatory cytokines. Nmd3, Bcl2, Nhp2l1 may be important drug targets, establishing the role of BJOE in the treatment of lung cancer induced cachexia.


Asunto(s)
Brucea/química , Caquexia/tratamiento farmacológico , Carcinoma Pulmonar de Lewis/tratamiento farmacológico , Carcinoma Pulmonar de Lewis/metabolismo , Aceites de Plantas/farmacología , Animales , Peso Corporal/efectos de los fármacos , Caquexia/etiología , Caquexia/metabolismo , Caquexia/patología , Carcinoma Pulmonar de Lewis/patología , Ingestión de Alimentos/efectos de los fármacos , Emulsiones/química , Emulsiones/farmacología , Interleucina-6/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Aceites de Plantas/química , Proteínas Proto-Oncogénicas c-bcl-2/sangre , Proteínas de Unión al ARN/sangre , Distribución Aleatoria , Ribonucleoproteínas Nucleares Pequeñas/sangre , Factor de Necrosis Tumoral alfa/sangre
3.
Artículo en Inglés | MEDLINE | ID: mdl-23502135

RESUMEN

Health and nutrition modulate postnatal growth. The availability of amino acids and energy, and insulin and insulin-like growth factor-I (IGF-I) regulates early growth through the mTOR pathway. Amino acids and glucose also stimulate the secretion of IGF-I and insulin. Postnatal growth induces lasting, programming effects on later body size and adiposity in animals and in human observational studies. Rapid weight gain in infancy and the first 2 years was shown to predict increased obesity risk in childhood and adulthood. Breastfeeding leads to lesser high weight gain in infancy and reduces obesity risk in later life by about 20%, presumably partly due to the lower protein supply with human milk than conventional infant formula. In a large randomized clinical trial, we tested the hypothesis that reduced infant formula protein contents lower insulin-releasing amino acid concentrations and thereby decrease circulating insulin and IGF-I levels, resulting in lesser early weight gain and reduced later obesity risk (the 'Early Protein Hypothesis'). The results demonstrate that lowered protein in infant formula induces similar - but not equal - metabolic and endocrine responses and normalizes weight and BMI relative to breastfed controls at the age of 2 years. The results available should lead to enhanced efforts to actively promote, protect and support breastfeeding. For infants that are not breastfed or not fully breastfed, the use of infant formulas with lower protein contents but high protein quality appears preferable. Cows' milk as a drink provides high protein intake and should be avoided in infancy.


Asunto(s)
Lactancia Materna , Fórmulas Infantiles , Fenómenos Fisiológicos Nutricionales del Lactante , Leche Humana , Aminoácidos/sangre , Aminoácidos de Cadena Ramificada/sangre , Animales , Glucemia/análisis , Índice de Masa Corporal , Péptido C/orina , Proteínas en la Dieta/administración & dosificación , Humanos , Lactante , Insulina/sangre , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/sangre , Factor I del Crecimiento Similar a la Insulina/análisis , Factor I del Crecimiento Similar a la Insulina/metabolismo , Leche , Estado Nutricional , Obesidad/prevención & control , Proteínas de Unión al ARN/sangre , Factores de Riesgo , Urea/sangre , Aumento de Peso/fisiología
4.
J Exp Clin Cancer Res ; 31: 76, 2012 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-22986368

RESUMEN

BACKGROUND: Treatment protocols for nasopharyngeal carcinoma (NPC) developed in the past decade have significantly improved patient survival. In most NPC patients, however, the disease is diagnosed at late stages, and for some patients treatment response is less than optimal. This investigation has two aims: to identify a blood-based gene-expression signature that differentiates NPC from other medical conditions and from controls and to identify a biomarker signature that correlates with NPC treatment response. METHODS: RNA was isolated from peripheral whole blood samples (2 x 10 ml) collected from NPC patients/controls (EDTA vacutainer). Gene expression patterns from 99 samples (66 NPC; 33 controls) were assessed using the Affymetrix array. We also collected expression data from 447 patients with other cancers (201 patients) and non-cancer conditions (246 patients). Multivariate logistic regression analysis was used to obtain biomarker signatures differentiating NPC samples from controls and other diseases. Differences were also analysed within a subset (n=28) of a pre-intervention case cohort of patients whom we followed post-treatment. RESULTS: A blood-based gene expression signature composed of three genes - LDLRAP1, PHF20, and LUC7L3 - is able to differentiate NPC from various other diseases and from unaffected controls with significant accuracy (area under the receiver operating characteristic curve of over 0.90). By subdividing our NPC cohort according to the degree of patient response to treatment we have been able to identify a blood gene signature that may be able to guide the selection of treatment. CONCLUSION: We have identified a blood-based gene signature that accurately distinguished NPC patients from controls and from patients with other diseases. The genes in the signature, LDLRAP1, PHF20, and LUC7L3, are known to be involved in carcinoma of the head and neck, tumour-associated antigens, and/or cellular signalling. We have also identified blood-based biomarkers that are (potentially) able to predict those patients who are more likely to respond to treatment for NPC. These findings have significant clinical implications for optimizing NPC therapy.


Asunto(s)
Biomarcadores de Tumor , Regulación Neoplásica de la Expresión Génica , Neoplasias Nasofaríngeas , Transcriptoma , Proteínas Adaptadoras Transductoras de Señales/sangre , Adulto , Anciano , Antígenos de Neoplasias/sangre , Biomarcadores de Tumor/sangre , Biomarcadores de Tumor/genética , Carcinoma , Proteínas de Unión al ADN , Femenino , Perfilación de la Expresión Génica , Humanos , Masculino , Persona de Mediana Edad , Carcinoma Nasofaríngeo , Neoplasias Nasofaríngeas/sangre , Neoplasias Nasofaríngeas/metabolismo , Neoplasias Nasofaríngeas/patología , Proteínas Nucleares , Proteínas de Unión al ARN/sangre , Factores de Transcripción
5.
Asian Pac J Trop Biomed ; 1(2): 133-8, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23569743

RESUMEN

OBJECTIVE: To investigate the anti-diabetic and anti-cholesterolemic activity of methanol extracts of leaves of Amaranthus caudatus, Amaranthus spinosus and Amaranthus viridis in normal and streptozotocin (STZ) induced diabetic rats. METHODS: In this study, the anti-diabetic and anti-cholesterolemic activity of methanol extracts of leaves of all three plants was evaluated by using normal and STZ induced diabetic rats at a dose of 200 mg/kg and 400 mg/kg p.o. daily for 21 days. Blood glucose levels and body weight were monitored at specific intervals, and different biochemical parameters, serum cholesterol, serum triglyceride, high density lipoprotein, low density lipoprotein and very low density lipoprotein were also assessed in the experimental animals. Histology of pancreas was performed. RESULTS: It was found that all the three plants at 400 mg/kg dose showed significant anti-diabetic and anti-cholesterolemic activity (P<0.01), while at 200 mg/kg dose less significant anti-diabetic activity (P<0.05) was observed. CONCLUSIONS: Methanol extracts of Amaranthus caudatus, Amaranthus spinosus and Amaranthus viridis showed significant anti-diabetic and anti-cholesterolemic activity, which provides the scientific proof for their traditional claims.


Asunto(s)
Amaranthus/química , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Hipolipemiantes/administración & dosificación , Extractos Vegetales/administración & dosificación , Animales , Glucemia/metabolismo , Colesterol/sangre , Diabetes Mellitus Experimental/sangre , Femenino , Humanos , Masculino , Fitoterapia , Proteínas de Unión al ARN/sangre , Ratas , Ratas Wistar
6.
J Biol Chem ; 276(2): 1119-26, 2001 Jan 12.
Artículo en Inglés | MEDLINE | ID: mdl-11042220

RESUMEN

The signal transduction pathways regulating nucleolin mRNA and protein production have yet to be elucidated. Peripheral blood mononuclear cells treated with phorbol 12-myristate 13-acetate showed steady state levels of nucleolin mRNA that were 2-2.5-fold greater than untreated control cells. The up-regulation of nucleolin mRNA was substantially repressed by U0126, a specific inhibitor that blocks phosphorylation of extracellular-regulated kinase (ERK). Calcium ionophores and ionomycin also activated ERK and substantially elevated nucleolin mRNA levels, demonstrating phorbol 12-myristate 13-acetate and calcium signaling converge on ERK. Drugs that affected protein kinase C, protein kinase A, and phospholipase C signal transduction pathways did not alter nucleolin mRNA levels significantly. The half-life of nucleolin mRNA increased from 1.8 h in resting cells to 3.2 h with phorbol ester activation, suggesting ERK-mediated posttranscriptional regulation. Concomitantly, full-length nucleolin protein was increased. The higher levels of nucleolin protein were accompanied by increased binding of a 70-kDa nucleolin fragment to the 29-base instability element in the 3'-untranslated region of amyloid precursor protein (APP) mRNA in gel mobility shift assays. Supplementation of rabbit reticulocyte lysate with nucleolin decreased APP mRNA stability and protein production. These data suggest ERK up-regulates nucleolin posttranscriptionally thereby controlling APP production.


Asunto(s)
Regulación de la Expresión Génica , Leucocitos Mononucleares/metabolismo , Proteínas Quinasas Activadas por Mitógenos/sangre , Proteínas Nucleares/genética , Fosfoproteínas/genética , Proteínas de Unión al ARN/genética , Transcripción Genética/efectos de los fármacos , Regiones no Traducidas 3'/genética , Adenilil Ciclasas/metabolismo , Precursor de Proteína beta-Amiloide/genética , Animales , Calcimicina/farmacología , AMP Cíclico/farmacología , Proteínas Quinasas Dependientes de AMP Cíclico/sangre , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Técnicas In Vitro , Cinética , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Sistema de Señalización de MAP Quinasas/fisiología , Proteínas Nucleares/sangre , Fosfoproteínas/sangre , Biosíntesis de Proteínas , Proteína Quinasa C/sangre , ARN Mensajero/sangre , Proteínas de Unión al ARN/sangre , Conejos , Reticulocitos/metabolismo , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Acetato de Tetradecanoilforbol/farmacología , Fosfolipasas de Tipo C/sangre , Nucleolina
7.
Arch Biochem Biophys ; 325(2): 295-303, 1996 Jan 15.
Artículo en Inglés | MEDLINE | ID: mdl-8561510

RESUMEN

The regulation of expression of hepatic iron-related proteins was examined during iron deficiency caused by scurvy in guinea pigs. Previous studies showed that some effects of scurvy, such as suppression of collagen gene expression, result from events associated with weight loss. During the initial phase of scurvy when vitamin C is depleted but animals grow normally, serum iron levels decreased to 50% of normal. During the second phase of scurvy when animals lose weight, there was a further decrease in iron levels to 10-15% of normal. Serum transferrin levels increased during scurvy, but this increase was related neither to the rate of weight loss nor to hepatic transferrin mRNA expression, which decreased. Serum ferritin levels of diminished early in scurvy with a preferential loss of the L subunit. In liver, however, both ferritin animals gaining weight. Ferritin gene expression during vitamin C deficiency was correlated with serum ferritin levels in that the level of mRNA for the H subunit remained relatively constant while that of the L subunit decreased early. Transferrin receptor mRNA expression in liver was induced as soon as iron levels decreased early in scurvy, which is similar to results reported for iron-depleted cultured cells. In contrast to results in cell culture, expression of iron regulatory protein 1 mRNA was decreased to approximately 50% of normal early in scurvy with a concomitant decrease in hepatic cytosolic aconitase activity. Our data indicate that iron deficiency occurs early during vitamin C deficiency and leads to changes in expression of iron-related proteins that differ in some aspects from regulation by iron in cell culture. Other events associated with weight loss in late scurvy may play a further role in this regulation.


Asunto(s)
Deficiencias de Hierro , Proteínas/genética , Escorbuto/genética , Aconitato Hidratasa/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Citosol/enzimología , ADN Complementario/genética , Ferritinas/química , Ferritinas/genética , Regulación de la Expresión Génica , Cobayas , Hierro/sangre , Proteínas Reguladoras del Hierro , Hígado/metabolismo , Datos de Secuencia Molecular , Sondas de Oligonucleótidos/genética , Conformación Proteica , Proteínas/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Proteínas de Unión al ARN/sangre , Proteínas de Unión al ARN/genética , Receptores de Transferrina/genética , Escorbuto/complicaciones , Escorbuto/metabolismo , Transferrina/genética , Transferrina/metabolismo , Pérdida de Peso/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA